Dr. Reddy's Laboratories wins US FDA approval for rituximab biosimilar
Business
Dr. Reddy's Laboratories just got US FDA approval for its rituximab biosimilar, a version of the cancer and autoimmune drug Rituxan.
Made at their Hyderabad facility, this win gives Dr. Reddy's a stronger presence in the US pharmaceutical scene.
Fresenius Kabi to handle US marketing
Fresenius Kabi will handle all US marketing for this biosimilar, which is already available in India, across Europe, and more than 25 emerging markets.
Rituximab is used to treat conditions like non-Hodgkin lymphoma and certain autoimmune diseases, so this move could make life-saving therapies more accessible for patients who need them most.
Dr. Reddy's has been expanding its biologics lineup, aiming to reach more people with critical treatments.